Solana Beach, CA, United States of America

Richard Allen Houghten

USPTO Granted Patents = 93 (Patent Applications = 5)

Average Co-Inventor Count = 2.9

ph-index = 23

Forward Citations = 1,838(Granted Patents)

Forward Citations (Not Self Cited) = 1,782(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Solhna Beach, CA (US) (1987)
el Mar, CA (US) (2001)
Solano Beach, CA (US) (2003)
Del Mar, CA (US) (1994 - 2008)
Solana Beach, CA (US) (1985 - 2013)
Point Saint Lucie, FL (US) (2018)
Vero Beach, FL (US) (2009 - 2019)
Port St. Lucie, FL (US) (2018 - 2024)

Company Filing History:

35 out of 45

Torrey Pines Institute for Molecular Studies

patents

19 out of 122

Scripps Clinic and Research Foundation

patents

10 out of 22

Trega Biosciences, Inc.

patents

4. 5 out of 6

Houghten Pharmaceuticals, Inc.

patents

5. 4 out of 4

Mixture Sciences, Inc.

University of South Florida

patents

8. 3 out of 290

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Louisiana State University and Agricultural & Mechanical College

patents

11. 2 out of 1,186

The Scripps Research Institute

patents

12. 2 out of 94

The Burnham Institute

patents

13. 2 out of 2

Torry Pines Institute for Molecular Studies

patents

14. 2 out of 2,304

University of Minnesota

University of California

patents

17. 2 out of 22

Merrion Research Iii Limited

patents

18. 1 out of 1

Houghten Pharmaceutical Inc.

patent

19. 1 out of 1

Lion Bioscience Science Ag

patent

20. 1 out of 3,580

American Cyanamid Company

patents

21. 1 out of 1

Torrey Pines Institute

patent

22. 1 out of 2,925

University of Florida Research Foundation, Incorporated

Florida International University

26. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2024

Loading Chart...

93 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11932628 - Selective small molecule peptidomimetic melanocortin ligands (2024-03-19),

2. 11352370 - Mutant KRAS inhibitors (2022-06-07),

3. 11014876 - Polyamine sulfonamides and uses thereof (2021-05-25),

4. 10899793 - Melanocortin ligands and methods of use thereof (2021-01-26),

5. 10711014 - Mutant KRas inhibitors (2020-07-14),

6. 10421764 - Mutant KRas inhibitors (2019-09-24),

7. 10258664 - Methods and compositions for treating pain (2019-04-16),

8. 10085981 - Protein acyl transferase inhibitors and methods of treatment (2018-10-02),

9. 10052309 - Bis-cyclic guanidine compound compositions, methods of use and treatment thereof (2018-08-21),

10. 10048272 - High-affinity small molecule formylpeptide receptor ligands from screening of combinatorial mixture-based libraries (2018-08-14),

11. 9994536 - Compounds and methods of treating neurological disorders (2018-06-12),

12. 9988341 - Bacterial topoisomerase inhibitors and use thereof (2018-06-05),

13. 9782388 - BIS-cyclic guanidine compound compositions, methods of use and treatment thereof (2017-10-10),

14. 9610351 - Methods and compositions for treating pain (2017-04-04),

15. 9310364 - High-affinity small molecule formylpeptide receptor ligands from screening of combinatorial mixture-based libraries (2016-04-12),

Title: Innovator Spotlight: Richard Allen Houghten

Introduction:

Richard Allen Houghten, a prolific inventor based in Solana Beach, CA, is a trailblazer in the field of oncology with an impressive portfolio of 58 patents. His groundbreaking work has significantly advanced the development of novel therapies for treating cancers involving overactive Ras signaling.

Latest Patents:

Houghten's latest patents include innovative inventions such as Mutant KRAS inhibitors and Polyamine sulfonamides. These compounds demonstrate promising antineoplastic activity and show great potential in the treatment and prevention of cancer, addressing the critical unmet medical need for effective therapeutics in oncology.

Career Highlights:

Throughout his career, Houghten has been associated with esteemed research institutions such as the Torrey Pines Institute for Molecular Studies and the Scripps Clinic and Research Foundation. His expertise and dedication to scientific advancement have led to the successful development of transformative pharmaceutical compounds.

Collaborations:

Houghten has collaborated closely with notable colleagues in his field, including John M Ostresh and Clemencia Pinilla. Together, they have worked synergistically to push the boundaries of innovation in oncology research, paving the way for new therapeutic approaches and treatment modalities.

Conclusion:

In conclusion, Richard Allen Houghten's pioneering work in oncology has significantly contributed to the advancement of cancer treatment strategies. His dedication to developing novel compounds and methodologies underscores his commitment to improving patient outcomes and addressing the unmet medical needs in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

5 patents pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.